STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Clinical trials for STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug plus radiation aims to tackle returning head and neck cancers
Disease control Recruiting nowThis early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …
Matched conditions: STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Matched conditions: STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Matched conditions: STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis phase II trial tests whether adding BMX-001 to standard symptom management can reduce severe mouth sores in head and neck cancer patients receiving chemoradiation. About 98 participants will receive either BMX-001 or a placebo alongside usual care. The goal is to see if BMX-…
Matched conditions: STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New hope for cancer patients: drug may replace opioids for mouth sore pain
Symptom relief Recruiting nowThis study tests whether a high dose of gabapentin, a non-opioid pain medicine, can prevent the need for opioid painkillers in people with head and neck cancer who develop painful mouth sores from chemotherapy and radiation. About 228 participants will be randomly assigned to rec…
Matched conditions: STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC